|
JP5253401B2
(ja)
|
2006-09-07 |
2013-07-31 |
アクテリオン ファーマシューティカルズ リミテッド |
免疫調節薬としてのピリジン−４−イル誘導体
|
|
DK2125797T3
(da)
|
2007-03-16 |
2014-02-10 |
Actelion Pharmaceuticals Ltd |
Aminopyridinderivater som s1p1/edg1-receptoragonister
|
|
EP2195311B1
(en)
|
2007-08-17 |
2011-03-23 |
Actelion Pharmaceuticals Ltd. |
Pyridine derivatives as s1p1/edg1 receptor modulators
|
|
BRPI0818804A2
(pt)
|
2007-11-01 |
2015-04-22 |
Actelion Pharmaceuticals Ltd |
Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
|
|
BRPI0820868A2
(pt)
|
2007-12-10 |
2019-09-24 |
Actelion Pharmaceuticals Ltd |
composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
|
|
MX2010009645A
(es)
|
2008-03-07 |
2010-09-28 |
Actelion Pharmaceuticals Ltd |
Derivados novedosos de aminometil benceno.
|
|
PT2291080E
(pt)
|
2008-05-14 |
2015-10-30 |
Scripps Research Inst |
Novos modelamodeladores dos recetores da esfingosina fosfato
|
|
ES2714453T3
(es)
*
|
2008-06-09 |
2019-05-28 |
Univ Muenchen Ludwig Maximilians |
Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
|
|
EP2297139A1
(en)
*
|
2008-06-20 |
2011-03-23 |
Glaxo Group Limited |
Compounds
|
|
CN104311472B9
(zh)
|
2008-07-23 |
2020-03-17 |
艾尼纳制药公司 |
经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
|
|
PL2342205T4
(pl)
|
2008-08-27 |
2016-12-30 |
|
Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
|
|
WO2010085581A1
(en)
|
2009-01-23 |
2010-07-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
EP2389377B1
(en)
|
2009-01-23 |
2014-07-16 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
ES2405054T3
(es)
|
2009-01-23 |
2013-05-30 |
Bristol-Myers Squibb Company |
Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
|
|
TWI410421B
(zh)
|
2009-07-16 |
2013-10-01 |
Actelion Pharmaceuticals Ltd |
吡啶－４－基衍生物
|
|
US8399451B2
(en)
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
PL2498610T5
(pl)
*
|
2009-11-13 |
2024-11-04 |
Receptos Llc |
Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
|
|
HUE036391T2
(hu)
*
|
2009-11-13 |
2018-07-30 |
Celgene Int Ii Sarl |
Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
|
|
AU2015202660B2
(en)
*
|
2009-11-13 |
2016-10-27 |
Receptos Llc |
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
|
|
CN105130922A
(zh)
*
|
2009-11-13 |
2015-12-09 |
瑞塞普托斯公司 |
选择性的杂环1-磷酸鞘氨醇受体调节剂
|
|
EP2528894A1
(en)
|
2010-01-27 |
2012-12-05 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
|
CN105503882B
(zh)
|
2010-03-03 |
2019-07-05 |
艾尼纳制药公司 |
制备s1p1受体调节剂及其晶体形式的方法
|
|
EP2390252A1
(en)
*
|
2010-05-19 |
2011-11-30 |
Almirall, S.A. |
New pyrazole derivatives
|
|
WO2012040532A1
(en)
*
|
2010-09-24 |
2012-03-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole compounds and their use as s1p1 agonists
|
|
CA2818470C
(en)
|
2011-01-19 |
2019-03-05 |
Actelion Pharmaceuticals Ltd |
2-methoxy-pyridin-4-yl derivatives
|
|
WO2012118935A1
(en)
|
2011-03-03 |
2012-09-07 |
Proteotech Inc |
Compounds for the treatment of neurodegenerative diseases
|
|
CN102718726A
(zh)
*
|
2011-03-31 |
2012-10-10 |
上海铂力生物科技有限公司 |
作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
|
|
US9481659B2
(en)
|
2011-05-13 |
2016-11-01 |
Celgene International Ii Sàrl |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
JP6105594B2
(ja)
|
2011-09-30 |
2017-03-29 |
エンドゥ ファーマシューティカルズ，インコーポレイティド |
癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
MX376108B
(es)
|
2012-12-20 |
2025-03-07 |
Tempest Therapeutics Inc |
Compuestos de triazolona y usos de los mismos.
|
|
HUE039931T2
(hu)
|
2013-02-20 |
2019-02-28 |
Lg Chemical Ltd |
Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
|
|
HRP20171763T1
(hr)
*
|
2013-03-15 |
2017-12-29 |
Idorsia Pharmaceuticals Ltd |
Derivati piridin-4-ila
|
|
AU2014315151A1
(en)
|
2013-09-06 |
2016-03-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
WO2015066515A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Receptos, Inc. |
Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
|
|
US9828351B2
(en)
*
|
2014-06-26 |
2017-11-28 |
Monash University |
Enzyme interacting agents
|
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
|
US20180016244A1
(en)
|
2015-04-06 |
2018-01-18 |
Auspex Pharmaceuticals, Inc. |
Deuterium-substituted oxadiazoles
|
|
ES2770348T3
(es)
|
2015-05-20 |
2020-07-01 |
Idorsia Pharmaceuticals Ltd |
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
|
|
JP6838744B2
(ja)
|
2015-06-22 |
2021-03-03 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
|
|
PL3470400T3
(pl)
|
2016-06-14 |
2025-08-04 |
Receptos Llc |
Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania
|
|
CN109563059A
(zh)
|
2016-08-19 |
2019-04-02 |
苏州科睿思制药有限公司 |
奥扎莫德的晶型及其制备方法
|
|
EP3508481A1
(en)
|
2016-09-14 |
2019-07-10 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal form of ozanimod hydrochloride, and preparation method therefor
|
|
CA3038106A1
(en)
|
2016-09-29 |
2018-04-05 |
Celgene International Ii Sarl |
Compounds and methods for treating lupus
|
|
CA3051095A1
(en)
|
2017-01-23 |
2018-07-26 |
Naqi Logics, Llc |
Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution
|
|
KR20190113955A
(ko)
|
2017-02-16 |
2019-10-08 |
아레나 파마슈티칼스, 인크. |
장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
|
|
CN110520124A
(zh)
|
2017-02-16 |
2019-11-29 |
艾尼纳制药公司 |
用于治疗原发性胆汁性胆管炎的化合物和方法
|
|
CN110325517B
(zh)
*
|
2017-02-28 |
2021-03-02 |
南京明德新药研发有限公司 |
螺环类化合物及其应用
|
|
WO2018211323A1
(en)
*
|
2017-05-17 |
2018-11-22 |
Oppilan Pharma Ltd. |
Hetercyclic compounds for the treatment of disease
|
|
WO2019042219A1
(zh)
|
2017-08-31 |
2019-03-07 |
苏州科睿思制药有限公司 |
奥扎莫德盐酸盐的晶型及其制备方法
|
|
WO2019094409A1
(en)
|
2017-11-07 |
2019-05-16 |
Teva Pharmaceuticals International Gmbh |
Salts and solid state forms of ozanimod
|
|
JP7397011B2
(ja)
|
2018-06-06 |
2023-12-12 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１ｐ１受容体に関連する状態を治療する方法
|
|
EP3847158B1
(en)
|
2018-09-06 |
2026-06-24 |
Arena Pharmaceuticals, Inc. |
Compounds useful in the treatment of autoimmune and inflammatory disorders
|
|
AR116479A1
(es)
|
2018-09-25 |
2021-05-12 |
Quim Sintetica S A |
Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
|
|
WO2020152718A1
(en)
|
2019-01-25 |
2020-07-30 |
Mylan Laboratories Limited |
Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
|
|
US20220227722A1
(en)
*
|
2019-04-26 |
2022-07-21 |
Receptos Llc |
Sphingosine 1 phosphate receptor modulator
|
|
CN112062785B
(zh)
*
|
2019-06-11 |
2023-06-27 |
广东东阳光药业有限公司 |
奥扎莫德及其中间体的制备方法
|
|
WO2021026479A1
(en)
*
|
2019-08-07 |
2021-02-11 |
Stamford, Andrew |
Small molecule inhibitors of s1p2 receptor and uses thereof
|
|
KR20220119653A
(ko)
|
2019-12-20 |
2022-08-30 |
테나야 테라퓨틱스, 인코포레이티드 |
플루오로알킬-옥사디아졸 및 이의 용도
|
|
KR20220158743A
(ko)
|
2020-03-27 |
2022-12-01 |
리셉토스 엘엘씨 |
스핑고신 1 포스페이트 수용체 조절제
|
|
ES3068582T3
(en)
*
|
2020-03-27 |
2026-06-01 |
Receptos Llc |
Sphingosine 1 phosphate receptor modulators
|
|
KR20220158745A
(ko)
|
2020-03-27 |
2022-12-01 |
리셉토스 엘엘씨 |
스핑고신 1 포스페이트 수용체 조절제
|
|
WO2021207051A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Bristol-Myers Squibb Company |
Methods of treating acute respiratory disorders
|
|
WO2021262311A1
(en)
*
|
2020-06-26 |
2021-12-30 |
The Penn State Research Foundation |
Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
|
|
US20230265082A1
(en)
*
|
2020-08-10 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
US20240252502A1
(en)
|
2021-05-04 |
2024-08-01 |
Tenaya Therapeutics, Inc. |
Hdac6 inhibitors for treatment of metabolic disease and hfpef
|
|
WO2023152767A1
(en)
|
2022-02-11 |
2023-08-17 |
Mylan Laboratories Limited |
Polymorphic forms of ozanimod hydrochloride
|
|
WO2024117172A1
(ja)
|
2022-11-30 |
2024-06-06 |
花王株式会社 |
痒みの予防又は改善剤
|
|
CN121194965A
(zh)
|
2023-05-31 |
2025-12-23 |
奎米卡新特缇卡股份有限公司 |
盐酸奥扎莫德的无定形形式和晶型
|
|
CN119320366B
(zh)
*
|
2023-07-17 |
2025-11-18 |
中国医学科学院药物研究所 |
取代萘甲基噁二唑-苯胺类化合物及其用途
|
|
US11905265B1
(en)
*
|
2023-10-13 |
2024-02-20 |
King Faisal University |
3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
AU2024406222A1
(en)
|
2023-12-20 |
2026-06-04 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
|